Aptinyx’s NYX-2925 Draws Skepticism As It Fails Another Trial

 
• By Alaric DeArment
Aptinyx said its Phase IIb trial of NYX-2925 in diabetic peripheral neuropathy did not meet its primary endpoint • Source: Alamy

More from Clinical Trials

More from R&D